GLA-SE

BIOLOGICAL8 trials

Sponsors

Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Access to Advanced Health Institute (AAHI), Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), University Hospital Tuebingen

Conditions

Colorectal Cancer MetastaticHealthy VolunteersLeishmaniasisMalariaMalaria, AntepartumMerkel Cell CarcinomaTuberculosis

Phase 1

The Effects of GLA on Human Volunteers

CompletedNCT01397604

Rockefeller UniversityHealthy Volunteers

Start: 2011-07-31End: 2013-03-31Target: 32Updated: 2013-09-23

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

CompletedNCT01751048

National Institute of Allergy and Infectious Diseases (NIAID)Leishmaniasis

Start: 2013-03-31End: 2015-01-31Updated: 2017-01-02

The Effects of GLA (5 mcg) on Human Volunteers

CompletedNCT01864876

Access to Advanced Health Institute (AAHI)Healthy Volunteers

Start: 2012-09-30End: 2013-12-31Updated: 2014-02-26

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

CompletedNCT02035657

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Merkel Cell Carcinoma

Start: 2014-01-31End: 2018-03-31Updated: 2018-06-13

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

CompletedNCT02508376

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis

Start: 2015-10-22End: 2017-08-31Updated: 2017-09-15

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

CompletedNCT02647489

University Hospital TuebingenMalaria, Antepartum

Start: 2016-05-31End: 2017-11-10Updated: 2018-06-26

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

CompletedNCT02658253

Institut National de la Santé Et de la Recherche Médicale, FranceMalaria

Start: 2016-01-31End: 2019-02-21Updated: 2025-12-04

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

WithdrawnNCT03982121

Gustave Roussy, Cancer Campus, Grand ParisColorectal Cancer Metastatic

Start: 2019-06-04End: 2020-02-12Updated: 2020-02-17

Related Papers

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.

2023-03-0623 citations

Progress and Insights Toward an Effective Placental Malaria Vaccine.

2021-02-2529 citations

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.

2020-02-0495 citations

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Clinical Infectious Diseases2019-01-03150 citations

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.

2017-01-2512 citations

Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).

Journal of Clinical Oncology2016-05-207 citations

Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC).

Journal of Clinical Oncology2015-05-204 citations